Oral administration of misoprostol for labor induction: A randomized controlled trial

被引:73
作者
Windrim, R
Bennett, K
Mundle, W
Young, DC
机构
[1] GRACE GEN HOSP,DEPT OBSTET & GYNECOL,ST JOHNS,NF A1E IP9,CANADA
[2] MEM UNIV NEWFOUNDLAND,ST JOHNS,NF,CANADA
关键词
D O I
10.1016/S0029-7844(96)00523-6
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To evaluate the effectiveness, safety, and gastrointestinal tolerance of misoprostol taken orally for induction of labor, against our established protocol, with the interval from induction to vaginal birth as the primary outcome measure. Methods: Two hundred seventy-five women who presented with indication for induction of labor were assigned randomly to receive either 50 mu g of misoprostol orally every 4 hours as needed or treatment according to our established protocol (physician-chosen combinations of intracervical or vaginal prostaglandins every 4-6 hours, artificial rupture of membranes, and oxytocin infusion). Sample size was calculated with a two-tailed alpha = .05 and power of 95%. Results: The mean time (+/- standard deviation) to vaginal birth with oral misoprostol was 926 +/- 521 minutes versus 909 +/- 585 minutes with the established protocol, a nonsignificant difference. There were no clinically or statistically significant differences in maternal secondary outcome measures (cesarean rate, frequency of epidural use, perineal trauma, or manual removal of the placenta). There was no difference in frequency of maternal gastrointestinal side effects. Neonatal outcomes, including cord blood acid-base analysis, were not different. Conclusions: Oral misoprostol may be a new option for labor induction. It appears to be no less effective or safe than our usual regimen for induction of labor at term and is well tolerated. Further studies are warranted to confirm the safety of this approach and to determine optimal dose and frequency of administration. Copyright (C) 1997 by The American College of Obstetricians and Gynecologists.
引用
收藏
页码:392 / 397
页数:6
相关论文
共 21 条
[1]  
*AM COLL OB GYN, 1995, ACOG TECHN B, V207
[2]  
*AM COLL OBST GYN, 1994, ACOG COMM OP, V138
[3]  
*AM COLL OBST GYN, 1994, ACOG COMM OP, V137
[4]  
CURTIS P, 1978, J REPROD MED, V32, P91
[5]   UTERINE HYPERSTIMULATION AFTER LOW-DOSE PROSTAGLANDIN-E2 THERAPY - TOCOLYTIC TREATMENT IN 181 CASES [J].
EGARTER, CH ;
HUSSLEIN, PW ;
RAYBURN, WF .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (03) :794-796
[6]  
FLETCHER H, 1994, OBSTET GYNECOL, V83, P244
[7]   INTRAVAGINAL MISOPROSTOL AS A CERVICAL RIPENING AGENT [J].
FLETCHER, HM ;
MITCHELL, S ;
SIMEON, D ;
FREDERICK, J ;
BROWN, D .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1993, 100 (07) :641-644
[8]  
GARRIS RE, 1989, CLIN PHARMACY, V8, P627
[9]   METHOTREXATE AND MISOPROSTOL TO TERMINATE EARLY-PREGNANCY [J].
HAUSKNECHT, RU .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (09) :537-540
[10]   COMPARISON OF INTRAVAGINAL MISOPROSTOL WITH PROSTAGLANDIN-E(2) FOR TERMINATION OF 2ND-TRIMESTER PREGNANCY [J].
JAIN, JK ;
MISHELL, DR .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (05) :290-293